Despite the results of these promising large-scale clinical trials, a recently published analysis suggests that SGLT2 inhibitors remain underutilized in patients with CKD, especially in patients without diabetes mellitus (DM) (Zhuo et al., 2022). Here, SLC5A2 is linked to diabetes mellitus.